Phase II Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma
There have been no standard treatment in non-clear cell renal cell carcinoma. Retrospective
studies showed sunitinib or sorafenib might be active in non-clear cell renal cell
carcinoma, especially papillary type and chromophobe type.
This study is to evaluate efficacy and safety of sunitinib in this group of patients.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Tumor response is to be measured every 6 weeks. RECIST v.1.1 will be used to definte target lesion and non-target lesion and classify the response category.
up to 12 months
Jae-Lyun Lee, MD, PhD
Asan Medical Center
Korea: Food and Drug Administration